JDRF T1D Fund
Venture Capital
Active
Boston, United States
49
51M
32
6.12
6
0.35
8
- Areas of investment
Summary
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the JDRF T1D Fund, startups are often financed by Vatera Healthcare Partners, Visionnaire Ventures, Senvest Capital. The meaningful sponsors for the fund in investment in the same round are Visionnaire Ventures, Senvest Capital, Quadrant Capital Advisors. In the next rounds fund is usually obtained by Viva Ventures Biotech Group, Visionnaire Ventures, Total Access Fund.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2019. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this JDRF T1D Fund performs on 21 percentage points less the average number of lead investments. The important activity for fund was in 2017.
The overall number of key employees were 4.
Among the most successful fund investment fields, there are Biotechnology, Health Care. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Diasome, ImmusanT, Bigfoot Biomedical. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 49
- Lead investments
- 6
- Exits
- 8
- Rounds per year
- 6.12
- Follow on index
- 0.35
- Investments by industry
- Biotechnology (43)
- Health Care (22)
- Therapeutics (20)
- Medical (19)
- Life Science (18) Show 15 more
- Investments by region
-
- United States (40)
- United Kingdom (2)
- Canada (3)
- France (2)
- Italy (1) Show 1 more
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 89M
- Group Appearance index
- 0.88
- Avg. company exit year
- 8
- Avg. multiplicator
- 7.25
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Cour Pharmaceuticals Development | 30 Jan 2024 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 105M | United States, Illinois, Elmhurst |
| Sonoma BioTherapeutics | 30 Sep 2020 | Biotechnology, Life Science, Therapeutics | Early Stage Venture | 30M | United States, California, South San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.